← Back to news
NewsEMATuesday, March 10, 2026 · March 10, 2026

EMA Grants Conditional Approval for Novel SMA Therapy

WHY IT MATTERS

More treatment options mean better outcomes. Competition drives innovation.

EMA granted conditional authorization to a new oral therapy for spinal muscular atrophy.

Read the original at EMA ↗
FDA ApprovalDrug

Related conditions

Spinal muscular atrophy associated with central nervous system anomalySpinal muscular atrophy with respiratory distress type 2Spinal muscular atrophy with respiratory distress type 1

Related news

FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…